雷珠单抗治疗视网膜中央静脉阻塞引起的眼前段新生血管

发布时间：2018-02-01 03:36

本文关键词： 雷珠单抗视网膜中央静脉阻塞眼前段新生血管疗效　出处：《国际眼科杂志》2016年08期 　论文类型：期刊论文

【摘要】：目的:探讨雷珠单抗治疗视网膜中央静脉阻塞(central retinal vein occlusion,CRVO)引起的眼前段新生血管(anterior segment neovascularization,ASNV)的疗效。方法:回顾性研究,选取2013-01/2014-12我院门诊及住院的因CRVO引起的ASNV并经过雷珠单抗玻璃体腔注射治疗的连续病例18例18眼。观察患者的最佳矫正视力、眼压、虹膜情况、房角镜检查等,随访时间6~13(平均9.1±2.9)mo。结果:患者18例18眼都接受了雷珠单抗治疗,15例15眼行视网膜光凝,3例3眼因玻璃体混浊仅行抗VEGF治疗,1例1眼行青光眼阀植入。其中6例6眼为仅有虹膜新生血管而没有眼压升高的患者,这6例6眼患者经过雷珠单抗联合全视网膜光凝(panretinal photocoagulation,PRP)后视力提高,眼压控制。已经伴有新生血管性青光眼的患者中,经过雷珠单抗及PRP治疗后,眼压可以控制者4例4眼;另有7例7眼眼压在雷珠单抗治疗后可以降低,但仍需药物控制;1例1眼药物控制不良者植入青光眼阀治疗,术后眼压控制,但视力较注射雷珠单抗前变差。所有患者的虹膜新生血管均可以消退。结论:雷珠单抗可以有效地使虹膜新生血管消退并对眼压控制有所帮助,在早期没有眼压升高的时候效果更好,提示要早期发现虹膜血管并尽早干预。
[Abstract]:Objective: to investigate the treatment of central retinal vein occlusion of central retinal vein occlusion with Lei Zhu McAb. The efficacy of anterior segment neovascularization in anterior segment neovascularization caused by CRVO.Methods: a retrospective study. Eighteen consecutive cases (18 eyes) of ASNV caused by CRVO and treated by vitreous injection of Rayzumab were selected in our outpatient and inpatient department of 2013-01 / 2014-12. The most recent cases were observed. Good corrected vision. Intraocular pressure, iris condition, angle angle examination and so on were followed up for an average of 9.1 卤2.9 mo.Results: 18 patients (18 eyes) were treated with Leizhu McAb. 15 cases (15 eyes) were treated with retinal photocoagulation, 3 cases (3 eyes) with vitreous opacification were treated with anti VEGF only. One case (1 eye) underwent glaucoma valve implantation, 6 cases (6 eyes) were only iris neovascularization patients without intraocular pressure elevation (IOP). The visual acuity was improved in 6 patients (6 eyes) treated with Leizhu McAb combined with panretinal photocoagulation (PRP). Intraocular pressure control. Among the patients with neovascular glaucoma, intraocular pressure could be controlled in 4 cases (4 eyes) after treatment with Lei Zhu McAb and PRP. In other 7 cases, the intraocular pressure of 7 eyes could be decreased after the treatment of Lei Zhu McAb, but it still needed to be controlled by drugs. In one case, one eye with poor drug control was treated with glaucoma valve, and the intraocular pressure was controlled after operation. But the visual acuity was worse than that before injection of Lei Zhu McAb. All patients' iris neovascularization could recede. Conclusion: Threzumab can effectively reduce iris neovascularization and help to control intraocular pressure. The effect is better when there is no elevation of intraocular pressure early, suggesting early detection of iris vessels and early intervention.
【作者单位】：中国湖北省枣阳市中医院眼科;
【分类号】：R774.1
【正文快照】：

【相似文献】